<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650596</url>
  </required_header>
  <id_info>
    <org_study_id>301nlxnk</org_study_id>
    <nct_id>NCT02650596</nct_id>
  </id_info>
  <brief_title>Effects of GLP-1 on Chronic Heart Failure</brief_title>
  <official_title>Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators planned to evaluate the effects of liraglutide on left ventricular function
      in chronic heart failure patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like
      peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct
      effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide
      could improve left ventricular function in patients with acute myocardial infarction.
      However, the effects of GLP-1 on chronic heart failure patients with type 2 diabetes remain
      unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular
      function in chronic heart failure patients with type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular ejection fraction measured by 3D echocardiography</measure>
    <time_frame>3 months</time_frame>
    <description>The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by 3D echocardiography at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma NT-proBNP levels</measure>
    <time_frame>3 months</time_frame>
    <description>a change in plasma NT-proBNP levels at 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a change in 6-minute walk distance</measure>
    <time_frame>3 months</time_frame>
    <description>The change in 6-minute walk distance at 3 months after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in the incidences of treatment-emergent adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>differences in the incidences of treatment-emergent adverse events at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>GLP-1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>Liraglutide were taken daily for 3 months</description>
    <arm_group_label>GLP-1 group</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo were taken daily for 3 months</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic heart failure patients with type 2 diabetes (NYHA-class I, II or III) were
             eligible for the study

        Exclusion Criteria:

          -  CHF (NYHA class IV)

          -  Type 1 diabetes

          -  Hospitalisation due to incompensated heart disease within 30 days prior to
             randomisation

          -  Myocardial infarction within the past 3 months before screening

          -  Coronary revascularisation within the past 3 months before screening

          -  Atrial fibrillation with ventricular frequency &gt;100/min in rest

          -  ECG suggestive of malignant ventricular arrhythmia

          -  Prolonged QT-interval (&gt;500 ms)

          -  Valvular heart disease

          -  Current myocardial or pericardial infection

          -  Obstructive hypertrophic cardiomyopathy

          -  Cancer unless in complete remission for ≥5 years

          -  Acute pancreatitis

          -  Compromised kidney function (eGFR &lt;30 mL/min), dialysis or kidney transplantation

          -  History of thyroidea adenoma or carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Shi, M.D.</last_name>
      <phone>+8610-66876231</phone>
      <email>ggyyong@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yu Tang Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009 Feb 10;53(6):501-10. doi: 10.1016/j.jacc.2008.10.033.</citation>
    <PMID>19195607</PMID>
  </reference>
  <results_reference>
    <citation>Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016 Jun;52(3):516-26. doi: 10.1007/s12020-015-0798-0. Epub 2015 Nov 16.</citation>
    <PMID>26573925</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015 Nov;170(5):845-54. doi: 10.1016/j.ahj.2015.07.014. Epub 2015 Jul 26.</citation>
    <PMID>26542491</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Shi Yang</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

